



Exon-Skipped Dystrophins for Treatment of Duchenne Muscular Dystrophy: Mass Spectrometry Mapping of Most Exons and Cooperative Domain Designs Based on Single Molecule Mechanics

Christine Carag Krieger,^{1,2} Nishant Bhasin,^{1,2} Manorama Tewari,^{1,2} Andre E. X. Brown,^{1,2} Daniel Safer,^{1,3} H. Lee Sweeney,^{1,3} and Dennis E. Discher^{1,2,3*}

¹Pennsylvania Muscle Institute, University of Pennsylvania, Philadelphia

²Biophysical Engineering Lab, University of Pennsylvania, Philadelphia

³Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia

Received 2 July 2010; Revised 13 September 2010; Accepted 23 September 2010

Monitoring Editor: Bruce Goode

Force-bearing linkages between the cytoskeleton and extracellular matrix are clearly important to normal cell viability—as is evident in a disease such as Duchenne muscular dystrophy (DMD) which arises in the absence of the linkage protein dystrophin. Therapeutic approaches to DMD include antisense-mediated skipping of exons to delete nonsense mutations while maintaining reading frame, but the structure and stability of the resulting proteins are generally unclear. Here we use mass spectrometry to detect most dystrophin exons, and we express and physically characterize dystrophin “nano”-constructs based on multiexon deletions that might find use in a large percentage of DMD patients. The primary structure challenge is addressed first with liquid chromatography tandem mass spectrometry (LC-MS/MS) which can detect tryptic peptides from 53 of dystrophin’s 79 exons; equivalent information from immunodetection would require 53 different high-specificity antibodies. Folding predictions for the nano-constructs reveal novel helical bundle domains that arise out of exon-deleted “linkers,” while secondary structure studies confirm high helicity and also melting temperatures well above physiological. Extensional forces with an atomic force microscope nonetheless unfold the constructs, and the ensemble of unfolding trajectories reveal the number of folded domains, proving consistent with structure predictions. A mechanical cooperativity parameter for unfolding of tandem domains is also introduced as the best predictor of a multiexon deletion that is asymptomatic in humans. The results thereby provide insight and confidence in exon-skipped designs. © 2010 Wiley-Liss, Inc.

Key Words: dystrophin, exon skipping, folding, AFM

Introduction

Dystrophin constitutes a critical link between the force-generating cytoskeleton in muscle and the extracellular matrix (Fig. 1A). Mutations that block expression of dystrophin lead to Duchenne muscular dystrophy (DMD), while mutations—including exon deletions—that shorten dystrophin’s central rod domain can lead to more mild forms of Becker muscular dystrophy (BMD) or even prove asymptomatic. Dystrophin’s rod domain normally consists of two-dozen three-helix bundle domains that are the repeated domains in ubiquitously expressed spectrin superfamily proteins. In red blood cells, these spectrin repeats have been shown to unfold when cells are mechanically sheared at physiological fluid shear stresses [Johnson et al., 2007a], and single molecule extension by atomic force microscopy (AFM) has also shown that spectrin and dystrophin repeats unfold under similar forces [Bhasin et al., 2005]. However, the structure and stability of dystrophin deletants have been studied only to a limited extent and mostly in solution [Kahana et al., 1997; Ruszczak et al., 2009] although there is pressing need for deeper insight: emerging therapeutic efforts for DMD involve antisense-mediated deletion of “multiple exons” within the DMD gene’s 79 exons with the goal of skipping nonsense mutations while maintaining reading frame.

Combinations of antisense oligonucleotides (AONs) that are needed to target multiple exons (e.g., $\Delta 44\text{--}54$, Fig. 1B) can be problematic in application due in part to inefficient skipping [Aartsma-Rus et al., 2006, 2007], but one such AON cocktail has been theorized to rescue up to 63% of DMD patients by transforming the DMD phenotype into an asymptomatic or mild BMD phenotype [Bérout et al., 2007]. Human clinical trials with a single AON designed to skip exon 51 [van Deutekom et al., 2007] lead to modest levels of dystrophin expression (<35% of normal controls) using standard

Additional Supporting Information may be found in the online version of this article.

C. Carag Krieger and N. Bhasin contributed equally for this article.

*Address correspondence to: Dennis E. Discher, Biophysical Engineering Lab, University of Pennsylvania, 129 Towne Building, Philadelphia PA 19104, USA. E-mail: discher@seas.upenn.edu

Published online 30 September 2010 in Wiley Online Library (wileyonlinelibrary.com).




Fig. 1. Full-length and representative truncated, BMD dystrophin in the dystrophin–glycoprotein complex. Schematic of dystrophin and the dystroglycan complex. In normal skeletal muscle, the muscle cytoskeleton (actin) is linked by dystrophin to extracellular matrix via the cell membrane. Boxed inset illustrates crystal structure for tandem repeats 2–3 from actinin with triple helix repeats linked by a continuous and extended helix. (A) Wild-type and (B) truncated dystrophin corresponding to milder BMD phenotype with in-frame exon 17–40 deletion. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

antibody approaches that remain state of the art in expression analysis [Freund et al., 2007], but the limited availability of antibodies can be constraining if one needs to assess expression from every exon. Multiexon deletion studies would clearly benefit from such assessments, and initial efforts at proteomic profiling of dystrophin in muscle suggest detectability [Lewis et al., 2009]. Here we address this issue of primary structure coverage with liquid chromatography tandem mass spectrometry (LC-MS/MS), prior to focusing on secondary and tertiary structures of dystrophin deletants.

Exon deletions of potential interest for treating patients (Table I) generally disrupt dystrophin’s spectrin-like repeats since exons and repeats possess distinct phasing (Fig. 2). Truncated dystrophins might nonetheless fold to form novel repeat domains that contribute protective properties of the full-length protein, and proper insight into what constitutes functional dystrophin structures could help guide AON-achievable designs. Proline-rich “hinge” regions (H2, H3) appear unique to dystrophin when compared to spectrins and have been assumed to be unfolded, but there is evidence that H3 can lead to a mechanical coupling of repeats [Bhasin et al., 2005]. Such structure and stability issues have traditionally been studied in solution with chemical denaturants and nonphysiological temperature changes, while single molecule AFM studies now allow one to apply more relevant mechanical forces. Most AFM studies in the past have focused on obtaining deeper understanding of known folded structures; the goal here is to obtain novel insight into unknown structures. Homology modeling based on spectrin-type repeats is used here to predict the folding of domains that result from key exon deletions, and then domain structures and stability are assessed by thermal denaturation and AFM, with the latter providing insight into the number of folded domains and linker or hinge regions. We examine truncated dystrophins that naturally occur in BMD plus a truncated dystrophin not yet found in

any patients but predicted here to yield stably folded domains. Cooperative unfolding under force emerges as an important design parameter.

Results

Mass Spectrometry Mapping of Dystrophin Primary Structure

As AON (and RNAi) therapies emerge, there is an increasing need to detect and even quantify proteins with complex splicing patterns. Evidence of changes in RNA from polymerase chain reaction (PCR) or other methods is simply not sufficient and antibody-based methods do not always yield the same results; in the cited human trials, for example, the efficiencies of exon skipping ranged from 49 to 90% for four patients while the amount of dystrophin in total protein extracts (with one antibody in Westerns) ranged from 3 to 12% of that found in a control specimen and from 17 to 35% for the immunofluorescent intensity ratio of dystrophin to laminin $\alpha 2$ relative to control [van Deutekom et al., 2007]. LC-MS/MS of tryptic peptides has emerged over the last decade as a powerful new method to map proteins, and it is used here to map dystrophin primary structure and perhaps provide some realism to detailed protein analyses of multiexon deletions that are likely to be needed for most patients.

Numerous dystrophin peptides were detected in four of five LC-MS/MS studies of lysates from myotube cultures (see methods). Primary structure coverage of dystrophin in each run ranged from three to 20%, with a combined sequence coverage of 27%, and the 57 detectable peptides appear cumulatively scattered throughout the entire length of protein (Fig. 2). Indeed, when mapped back into the 79

Table I. Potential Dystrophin Deletants Created by Exon Skipping

Mutations found in Duchenne MD patients	Targeted exons for skipping	Total exon deletions	% DMD patients w/ • deletion (s) • point mutation in deleted exons	MD phenotype
Deletion exons 45–54	Exon 44	$\Delta 44-54^a$	66.6 20.4	Mild BMD
Deletion exon 45	Exon 46	$\Delta 45-46$	32.9 3.6	Not reported
Deletion exons 45–50	Exon 51	$\Delta 45-51^a$	58.9 13.2	Asymptomatic
Deletion exons 48–50	Exon 45 + Exon 51	$\Delta 45-51^a$	58.9 13.2	Asymptomatic
Deletion exons 46–51	Exon 45	$\Delta 45-51^a$	58.9 13.2	Asymptomatic
Deletion exons 46–50	Exon 45 + Exon 51	$\Delta 45-51^a$	58.9 13.2	Asymptomatic
Deletion exons 48–50	Exon 51	$\Delta 48-51$	22.4 8.3	Asymptomatic
Point Mutation exon 49	Exon 49	$\Delta 49^a$	4.5 1.0	BMD
Deletion exon 50	Exon 51	$\Delta 50-51$	9.0 4.9	BMD
Deletion exons 51–55	Exon 50	$\Delta 50-55$	12.4 8.8	Not reported
Deletion exon 52	Exon 51	$\Delta 51-52$	7.1 3.5	BMD
Deletion exon 52	Exon 51 + Exon 53	$\Delta 51-53$	8.3 4.3	BMD
Deletion exon 52	Exon 53	$\Delta 52-53$	3.0 1.7	BMD
		$\Delta 42-55^a$	68.8 20.4	Not found in any patient

^aA basis for constructs studied here.

exons that encode full-length dystrophin, 53 exons (or 67%) yield detectable tryptic peptides. To our knowledge, antibodies do exist to many of these exons. These cumulated MS results could therefore supplement (or replace!) immunodetection of exon-deleted forms of dystrophin; for example, in the four deletion constructs considered next, all yield peptides from exons that are immediately upstream and downstream of the deletion or else just one exon removed, and all but two of the deleted exons also yield detectable peptides. Because multiple AON's need to act on the same pre-mRNA in order to achieve the desired multiexon skipping, the ability to detect (and even quantify) peptides from supposedly deleted exons is necessary to troubleshoot the fidelity of splicing and to know the primary structure of protein or, very possibly, mixtures of protein spliceoforms actually expressed in patients treated with multiple AONs.

Dystrophin Nano-Constructs and Structural Predictions

DMD-causing mutations in a representative database [Fokkema et al., 2005] are summarized in Table I together with exons that would be targeted if these specific patients were to undergo AON-therapy. Percentages of DMD patients that have mutations in the deleted exons and would therefore have the same truncated dystrophin are also shown together with an indication of predicted phenotype (e.g., mild BMD), assuming that exon skipping works perfectly. There are many combinations of mutations and therapeutic deletions but only a handful of truncated dystrophins are functionally in-frame as illustrated with $\Delta 45-51$ which is the truncated dystrophin for four different DMD mutations. We designed nano-constructs of dystrophin (Fig. 3) based on four representative deletions: $\Delta 49$ has a typical

LEGEND

mono-skippable exons

18-58 = dispensable exons

Mass Spec detectable peptides with indicated sequence

N_p N = exon #; p = % deletion in human population (not point mutations)



Fig. 2. Phasing of DMD exons and protein domains with peptides detected by LC-MS/MS. 79 exons contribute to normal, full-length dystrophin, and, phasing of protein domains generally differs from exon boundaries. Each exon or repeat is numbered according to its distance from N-terminus, and the subscript indicates the percentage of DMD patients in the cited database [Fokkema et al., 2005] with that particular exon deletion or duplication. For LC-MS/MS results, mouse and human dystrophin sequences were aligned, and the location of the human analog of the mouse peptide shown in blue, with the indicated sequence of the detected peptide. About half of the detected tryptic peptides are identical between human and mouse and should translate to analyses of patients.




Fig. 3. Secondary and tertiary structure prediction of BMD-inspired nano-dystrophin constructs. (A) R16~L1~R21: (i) Exon map (ii) Secondary structure predictions for abnormal “linker,” L1, show this is mostly helical. Helical wheel predictions (not shown) indicate the presence of a hydrophobic core, necessitating packing of the helices into a spectrin-like domain. (iii) Homology model prediction for L1 with adjacent normal repeats shown in white. Color coding matches that of the structure prediction. (iv) Coomassie blue staining of purified nano-construct in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), with purity in densitometry of 99%. (B) R18~L1~R21: (i) Exon map. (ii) Linker region L2 is again predicted to be mostly helical and to form two spectrin-like domains. (iii) Homology model for L3 also predicts folding into two repeat domains. (iv) Purified protein. (C) R15~L3~R23: (i) Exon map. (ii) Secondary structure predictions predict L3 to be mostly helical with two spectrin-like domains. (iii) Homology model prediction shows linker L3 might also contain another kink or hinge-like domain as indicated by a white arrow. (iv) Purified protein. (D) R15~L4~R23. (i) Exon map. (ii) The linker region was predicted to be helical, with an unstructured coil region in the middle. (iii) Purified protein.

BMD phenotype, $\Delta 44-54$ has a milder BMD phenotype, $\Delta 45-51$ is completely asymptomatic, and $\Delta 42-55$ has not been found in any patients so far but is predicted to be in-frame.

In most types of structural studies of large proteins such as dystrophin, signals from the bulk of the protein dominate the

signal from any key region of interest, and so nano-constructs were designed here to maintain phasing with at least one repeat on either side of the deletion-created “linker” (Table II). L1 in the nano-construct R16~L1~R21 results, for example, from deletion of exons 45–51 (Fig. 3A). We distinguish native wild-type sequences from non-native sequences, respectively,

Table II. Predicted Unfolding Lengths of Domains in Dystrophin Nano-Constructs

Exon deletions (human phenotype)								
Domain	$\Delta 45-51$ (Asymptomatic) R16~L1~R21		$\Delta 49$ (BMD) R18~L2~R21		$\Delta 44-54$ (Mild) R15~L3~R23		$\Delta 42-55$ (n/a) R15~L4~R23	
	Name	l_c (nm)	Name	l_c (nm)	Name	l_c (nm)	Name	l_c (nm)
D1	R16	40.6	R18	40.6	R15	36.5	R15	36.5
D2	L1	39.9	L2 _a	42.0	L3 _a	42.4	L4	22.9
D3	R21	40.2	L2 _b	41.0	L3 _b	10.7	R23	47.6
D4	–	–	R21	40.2	L3 _c	39.0	–	–
D5	–	–	–	–	R23	47.6	–	–
Avg \pm SD		40.2 \pm 0.4		41.0 \pm 0.8		35.2 \pm 14.3		35.7 \pm 12.4

Table III. Thermal Denaturation of Dystrophin Nano-Constructs by CD and Tryptophan Fluorescence

Nano-construct (human phenotype)	CD T_m (°C)	%Helicity, 37°C		Tryptophan fluorescence T_m (°C)
		in PBS	w/TFE	
R16~L1~R21 ($\Delta 45-51$) (Asymptomatic)	60	54	85	55
R18~L2~R21 ($\Delta 49$) (BMD)	65	60	70	62
R15~L3~R23 ($\Delta 44-54$) (Mild)	55	58	75	35
R15~L4~R23 ($\Delta 42-55$) (N/A)	55	37	n/a	n/a

BMD denotes Becker MD, and n/a denotes not addressed.

with “-” versus “~.” Secondary structure and tertiary structure predictions were done on each linker region to assess whether: (1) the linker region can fold into a stable repeat domain, or (2) folding of the linker domain might disrupt folding of native neighboring domains. In the former case, the number of amino acids seems important: the linker region in construct R16~L1~R21 (Fig. 3B) has a contour length well within the range of a single repeat domain, whereas L2 in construct R18~L2~R21 appears long enough to fold into two domains. Interestingly, L2 does not result from splicing together of two repeat domains but instead results from splicing of a single repeat to the hinge H3 (Fig. 1A), which has been shown to be helical [Bhasin et al., 2005] but not necessarily folded into a stable tertiary structure. In contrast, linker L3 in construct R15~L3~R23 is too long for two repeat domains but falls short of forming three repeat domains, and L4 in R15~L4~R23 is much too short to generate even one repeat domain (Figs. 3C and 3D). This fact alone is not alarming because long helical linker regions between repeat domains are characteristic for this protein. In general, the helical content in the linker regions appears preserved, and tertiary folding through bundling of helices is driven by the need to shield hydrophobic patches. This occurs in L1, where one helix from repeat 17 easily substitutes for the missing helix in repeat 20. For simplicity, we refer to the various nano-constructs where appropriate as L1, L2, L3, or L4.

L2 proved an interesting case where the tertiary structure prediction shows warping or twisting in one of the novel repeat domains, most likely due to the flexibility of the hinge region. Despite, or perhaps because of, the flexibility in the hinge region, L2 was able to fold into two repeat domains. L3 was also able to fold into two repeat domains as well as a smaller, helical domain. The smaller domain formed between the two non-native repeat domains and is the residual of repeat 21. Its tertiary structure shields the hydrophobic patches that were exposed after removal of the majority of repeat 21. L4 had a similar problem where it was not long enough to form a full repeat domain. Only two of the three helices from repeat 22 remained. According to the “in-frame” model, repeats 15 and 23 in R15~L4~R23 were still in phase and should remain stable. One of the drawbacks of the structure predictions is that, due to the pre-exist-

ing helical nature of the peptide, the predictions will be biased towards giving the linker region a helical structure. However, doing so exposes hydrophobic patches on the helices, and whether that perturbation is strong enough to create a novel domain, as shown in L3, and whether that domain is stable under force must be determined experimentally.

Solution Studies by CD

Circular dichroism (CD) was used to measure thermal stability of the nano-constructs and to then estimate their helical content (e.g., Supporting Information Fig. S1). Melting temperature (T_m) provides a simple metric of thermal stability even though physiological temperatures rarely differ from 37°C, and we find that the melting temperatures of R16~L1~R21 and R18~L2~R21 (Table III) are both very close to the T_m reported for the full-length rod domain [Kahana et al., 1997]. R15~L3~R23 and R15~L4~R23 had slightly lower T_m , but all constructs should be highly stable at physiological 37°C.

For helicity determinations at 37°C, CD was done in phosphate buffered saline (PBS) with or without trifluoroethanol (TFE), which tends to stabilize helical structure to a maximum value less than 100% helicity. One hypothesis was that linker structures might not be especially stable in PBS at physiological temperature, and TFE might therefore increase %-helicity. Three of the four nano-constructs showed %-helicity well above 50%, consistent with a mostly helical bundle structure. With TFE, the asymptomatic nano-construct R16~L1~R21 showed the greatest helicity and the biggest change relative to PBS, but the fact that this deletant is asymptomatic in humans suggests this physically measurable difference in secondary structure is not critically important to structure-function. The R15~L4~R23 showed the lowest %-helicity overall, but %-helicity in TFE could not be determined because of TFE-induced aggregation; whether the low helicity was due to L4 being a random coil thus could not be determined.

Tryptophan fluorescence can be used to assess changes in solvated structure prior to or during complete unfolding. With R15~L4~R23, aggregation was again a problem. Two of the other three constructs showed T_m similar to those




Fig. 4. Single molecule extension by AFM reveals the unfolding forces and number of protein domains. (Top) Representative sawtooth patterns for domain-by-domain unfolding when extended at 1 nm/msec. (Bottom) Number of peaks, N_{pk} , per extension with pre-adsorbed nano-dystrophin constructs R18~L1~R21, R16~L2~R21 and R15~L3~R23. Each experiment involved at least 6000 contacts between AFM tip and proteinaceous substrate. For PBS alone, there were only zero to one peaks ever seen. The first peak and the last peak are ignored as desorption events, so that the number of mechanically detectable domains in is obtained by subtracting these two peaks from N_{pk} . [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

found by CD, but for R15~L3~R23 the T_m appeared near physiological temperature, indicating that for a significant fraction of this construct's 10 Trp's solvent exposure changes at physiological temperature. Two Trp's at the ends of repeats are predicted in modeling to be solvent exposed (thus constant signal). Four Trp's located in L3 (Fig. 3C) likely account for 50% of changes in signal intensity, and we speculate that these Trp's become exposed to solvent at lower temperature than the hydrophobic tryptophans sequestered in wild type dystrophin repeats 15 and 23 because the latter repeats have been recently expressed and reported to unfold with $T_m \sim 65^\circ\text{C}$ [Mirza et al., 2010]. CD and Trp fluorescence measurements therefore suggest that wild-type repeat domains induce helicity in L3 but these adjacent bundles have little influence on bundling into a physiologically stable tertiary structure.

Domain Counts and Lengths by Forced Extension

AFM was used to determine the number of unfoldable domains as well as the mechanical forces required to unfold stably folded domains. In such single molecule forced extension studies of spectrin family helical bundle proteins [Rief et al., 1999; Law et al., 2003; Bhasin et al., 2005], domains unfold in a stochastic fashion with force spectrograms

appearing as sawtooth patterns (Fig. 4, top). Such sawtooth patterns from tip retractions are unique to protein unfolding since other materials such as carbohydrates [Marszalek et al., 2003] and synthetic polymers [Sun and Walker, 2005] all reportedly show simpler, monotonic, stretching patterns. Thousands of pulling events here provide statistical fingerprints of mechanical unfolding for each nano-construct. If all of the predicted domains are stable, then the maximum number of peaks, $\max(N_{pk})$, seen in a large ensemble of force spectra would match the number of predicted domains plus two [Law et al., 2003]; the "two" accounts for tip desorption events at the beginning and end of a force pull and is based on systematic studies of multiple 2, 3, and 4 spectrin repeat constructs. For the deletion constructs of dystrophin tested here (Fig. 4, bottom), the AFM data thus indicates three domains in R16~L1~R21, four domains in R18~L2~R21, and five domains in R15~L3~R23—which are all in remarkable agreement with the tertiary structure predictions.

The force to a unfold a protein domain depends in general on the log of the extension rate, and \sim micrometer/second rates of muscle sarcomere contraction of order $\sim \mu\text{m}/\text{sec}$ suggest an extension rate of this magnitude is physiologically reasonable to apply. Past studies of forces to unfold spectrin repeats have revealed unfolding forces in the range of $\sim 20\text{--}40$ pN [Rief et al., 1999; Law et al., 2003; Bhasin et al., 2005], and the results here (Fig. 4, top) appear very similar in magnitude.

The peak-to-peak length (l_{pk-pk}) represents the extension of an unfolded domain before the next domain is stressed to unfold and it therefore defines a domain unfolding length. Furthermore, adjacent domains might be sufficiently coupled to sometimes unfold in tandem—as documented with doubled lengths for various constructs of spectrins [Law et al., 2003] as well as an R8-R15 dystrophin [Bhasin et al., 2005]. R16~L1~R21 was the one nano-construct here in which tandem unfolding pathways appear distinct as well as frequent: the cumulated histogram of l_{pk-pk} (Fig. 5A) shows a significant number of events for this deletion construct in which unfolding lengths appear at twice the unfolding length of ~ 20 nm that is typical of a single repeat domain [Law et al., 2003; Bhasin et al., 2005]. The widths of all distributions here are noticeably broader than those cited for single repeats. The increased widths highlight the greater diversity of pathways for extending these constructs with possibilities for unfolding "linker" domains separately or in tandem with canonical repeats.

The greater the number of peaks observed in a sawtooth pattern, the longer the total extension (Figs. 4, top, and 5B), even though sawtooths with very large N_{pk} are rare. The length limits calculated as contour lengths from the number of residues (gray regions in Fig. 5B; sums in Table II) are approached as expected only for extension curves at the $\max(N_{pk})$. The difference, Δ_u , between the maximum unfolded length and the contour length is just 15–25 nm and is much smaller than the $\Delta_u = 50$ nm reported previously for extension of constructs with dystrophin's native




Fig. 5. Unfolding length statistics by AFM for dystrophin nano-constructs. (A) Histograms for peak-to-peak unfolding lengths for R18~L1~R21, R16~L2~R21 and R15~L3~R23 all show a major peak that was fit with a Gaussian for single domain unfolding centered near ~20 nm. Peaks at ~2 \times and 3 \times the major peak value reflect simultaneous unfolding of multiple repeats. (B) After the 6000–8000 contacts of tip to surface, the total unfolding length (avg. \pm SD) beyond the second peak is obtained for each sawtooth, which is categorized by N_{pk} . The upper gray regions indicate the extension limits calculated from Table II, and the slope of the best-fit line through all of the data (including zero total unfolding length at $N_{pk} = 2$) is the average distance between peaks, which accounts for both single and multidomain unfolding. The lower bargraph shows frequency distributions of N_{pk} fitted to exponential decays of the form $m^{-N_{pk}}$ with $3 < N_{pk} < \max(N_{pk})$ and the indicated values for m . [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

hinge regions [Bhasin et al., 2005]. In the latter case, we concluded hinges extended before sawtooth-type unfolding of the repeats, whereas here Δ_u is so small that it likely reflects fraying or unwinding at the ends of domains.

The best-fit slope of the total unfolded length in a sawtooth versus the number of domains (Fig. 5B) shows for both R16~L1~R21 and R18~L2~R21 that the unfolding length per peak is significantly lower than the average domain contour lengths listed in Table II. These slopes reflect an averaging of single and multidomain unfolding events

and understandably exceed the ~20 nm length for the main peak seen in the l_{pk-pk} distributions. R15~L3~R23 was the only construct for which unfolding length per peak (31.5 nm/peak) and average domain contour length (Table II) were within one standard deviation (SD; 35.2 ± 14.3 nm domain).

The synthetic construct, R15~L4~R23, was shown above in solution studies to be structurally less stable than the asymptomatic and BMD-inspired constructs. While AFM extension results are not shown in additional detail here, the




Fig. 6. Forced unfolding of native dystrophin R8-R15 at different pulling rates and temperatures. While the effects of pulling rate are weak, they do suggest the expected log-dependence on pulling rate as well as a slight weakening of the interactions at the highest temperature, 34°C. Tandem unfolding events, with peak-to-peak unfolding lengths exceeding ~20 nm per Fig. 5A, are generally evident even at 34°C.

maximum peak number for R15~L4~R23 was found to be three, indicating that not even the two flanking wild-type repeats were stable. Additionally, the unfolding length per domain was only 17 nm, which shows that very few amino acids were in stable helical structures. This seemingly “negative” construct highlights the potential complexity that can result from deletion of multiple exons in dystrophin.

For completeness, we have also examined the rate dependence for forced unfolding of a fragment in dystrophin’s rod domain, R8-R15 (Fig. 6), up to near-physiological temperature (34°C). Past studies at room temperature have suggested this construct’s eight canonical spectrin repeats are interconnected by helical linkers that can propagate unfolding of up to four or five repeats as a single event—although such processes are exponentially more rare compared to single and tandem repeat unfolding [Bhasin et al., 2005]. The mean forces to unfold these canonical repeats increase only slightly with rate of pulling, consistent with reports for spectrin [Rief et al., 1999], and the forces decrease slightly with temperature up to near-physiological. Multirepeat unfolding was also evident at all temperatures, including near-physiological, with higher rates of pulling perhaps exhibiting more propagation of cooperative unfolding. The implications for rates of muscle contraction and cell pathophysiology are intriguing.

Discussion

Multixen deletions in both asymptomatic and BMD patients (Table I, Fig. 1B) lead to novel domain structures (Fig. 3 and Table II) with physical features both similar to and distinct from normal dystrophin. With DMD patients, similar structures might one day be generated by antisense-mediated skipping of exons—perhaps assessed at the primary structure level with Mass Spectrometry based mapping of exon expression (Fig. 2), but all such efforts seem likely to benefit from studies of secondary structure in solution combined with single molecule forced extension that reveals aspects of tertiary structure.

Helicity in solution together with melting temperatures are averaged properties that vary significantly here between nano-constructs (Table III) just as they do for isolated single repeats and tandem repeats [Mirza et al., 2010]. Such measurements might or might not lend insight into the function and mechanics of exon-deleted domains as suggested by the finding here that the one construct that represents an asymptomatic deletion (R16~L1~R21) exhibited the third lowest helicity and also showed the greatest disparity with TFE-induced helicity (Table III). On the other hand, solution studies did quickly demonstrate that R15~L4~R23, with its low helicity, tends to aggregate and might therefore be a poor design for multiexon skipping therapy.

Forced extension experiments (Figs. 4 and 5) agree with tertiary structure predictions in terms of the number of unfoldable domains, D , that one can determine from an ensemble of extension curves: $D = \max(N_{pk}) - 2$. The homology modeling here that also predicts D accounts for both helicity (i.e. hydrogen bonding) and packing of helices to sequester hydrophobic residues. We have previously simulated forced extension of tandem repeat spectrins by fully hydrated, atomistic molecular dynamics and found that helical linkers between domains can either (1) concentrate the strain and stochastically decouple domains or else (2) remain intact and facilitate unwinding and unfolding of the tandem [Ortiz et al., 2005]. The pulling experiments test the strength of the hydrophobic and hydrogen bonds within a domain, and ensemble-level analyses of such processes reveal the number of domains together with the range of forces holding the structures together. Unfolding forces of 20–40 pN are detected here (Figs. 4, top, and 6) seemingly independent of native domain or linker-derived domain and also independent of single or tandem unfolding, pulling rate or temperature (up to near-physiological), and such forces are typical of unfolding 3-helix bundle types of spectrin repeats [Rief et al., 1999; Law et al., 2003; Bhasin et al., 2005]. Myosin molecules individually generate peak forces on F-actin of about 6 pN at similar transition rates as here [Ishijima et al., 1996], which suggests that the collective action of a half-dozen myosin molecules is sufficient to extensibly unfold dystrophin in muscle. Spectrin in red blood cells has indeed




Fig. 7. Comparison of AFM measures of unfolding lengths and mechanical cooperativity for dystrophin nano-constructs here to prior results for native and mild-BMD constructs [Bhasin et al., 2005]. The exponential fits are for the prior results, and the dashed lines indicate deviation of results here from the prior results. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

been shown to unfold during fluid-shearing of these cells through the application of a novel “Cysteine Shotgun Mass Spectrometry” method in which in situ labeling of buried Cys is followed by Mass Spectrometry mapping of all labeled sites in lysates [Johnson et al., 2007a]. Among muscle proteins, titin’s repeat domains are known to unfold at much higher forces than spectrin repeats and calculations suggest that the probability of unfolding of some titin domains is low, but not zero in muscle [Li et al., 2002].

The predominant unfolding length per peak of ~ 20 nm for the nano-constructs (Fig. 5A) is also the same as that measured for wild-type dystrophin [Bhasin et al., 2005], and the additional distinct peak at twice this length for R16~L1~R21 provides clear evidence of cooperative tandem domain unfolding. With the other two constructs shown, the peak-to-peak length distributions are broad but do encompass all of the other expected domain transitions when scaled from the full contour length. Mixed modes of unfolding are also clear by comparing the ~ 20 nm histogram values to the significantly higher “mean unfolding length” determined from the slopes of total unfolded length versus number of domains, D (Fig. 5B). One additional metric of cooperative unfolding is revealed upon fitting the exponential decays of the N_{pk} distributions with

$$\text{Frequency}(N_{pk}) \sim m^{-N_{pk}} = (1/m)^{N_{pk}}$$

which yields values for $m > 1$. We have previously shown in systematic studies of short and long spectrin repeat constructs [Law et al., 2003] that m provides a simple measure of the m -fold fewer ways (i.e. degrees of freedom) for achieving one additional unfolded domain (single and tandem) in a protein that spans the gap between AFM tip and surface. For example, with D increasing from 2 to 4 in studies of

both α - and β -spectrin, m decreases exponentially from ~ 5 to ~ 3 ; theoretically, for $D = 2$, there are at most three unfolding pathways inasmuch as unfolding can involve one tandem repeat event and two single repeat events, whereas with $D = 4$, there are four possible single repeat events plus a combination of these with at least three tandem repeat events. Kinetic Monte Carlo simulations model this behavior with reasonable accuracy (Supporting Information Fig. S2). For the dystrophin nano-constructs here, $m = 2$ for the highly cooperative and asymptomatic R16~L1~R21 while $m = 4$ for the minimally cooperative BMD construct R18~L2~R21 and m is in between for the mild phenotype R15~L3~R23. Because of the inverse relationship, we introduce $1/m$ as a mechanical cooperativity metric in forced unfolding; $1/m$ ranges from 0 to 1 and the higher the value, the greater the mechanical cooperativity.

Past AFM results with the dystrophin rod domain R8-R15 and a mild BMD construct (H1-R1-2~H3~R22-24-H4) have indicated how both the Mean Unfolding Length per peak (i.e. slope) and the metric $1/m$ of cooperativity—as recognized here—vary with total domain number D (curves in Fig. 7), and the present results show that all of the nano-constructs here come close to previous results. Remarkably, both unfolding length and cooperativity are best preserved in the “asymptomatic” construct that deviates the least from past results. Cooperativity deviates the most for the “BMD” nano-construct, whereas unfolding length deviates the most for the “Mild” nano-construct. Mechanical cooperativity might be crucial to dystrophin function and might be the reason that the R16~L1~R21 deletion does not lead to BMD. Forced unfolding of multiple repeats all at once produces—in an instant—an extra long linker between contracting muscle and matrix, thereby maintaining cell anchorage.

Conclusions

Single molecule AFM studies here together with the various bioinformatics analyses clarify the structure and mechanical cooperativity of repeat domains in exon-skipped dystrophins. While solution studies provide basic information on secondary structure and stability, the single molecule mechanical studies reveal tertiary structures with helical domains formed by exon-deleted “linkers.” AFM extension experiments further suggest that mechanical cooperativity with tandem domain unfolding is particularly key to dystrophin function.

Materials and Methods

Mass Spectrometry

C2C12 myoblasts were cultured by established methods [e.g., Engler et al., 2004] and differentiated for 14 days. C2C12 lysates were prepared for standard one-dimensional-SDS-PAGE followed by in-gel trypsinization on the 460 kDa band that was then submitted for MS/MS following standard methods [Engler et al., 2008].

Structural Predictions

The helical content of nano-constructs was predicted using psi pred as described previously [Bhasin et al., 2005]. The hydrophobic packing of the helices was determined manually with helical wheel predictions that often indicated a hydrophobic core upon packing of the helices into a spectrin-like helical bundle domain. Homology prediction in conjunction with secondary structure predictions suggest that linking regions are purely helical and may fold into respective modular “molten” globules.

Plasmid Construction and Protein Preparation

Using native dystrophin as a guide, the dystrophin nano-constructs here were made by PCR per the designs of Figs. 2 and 3 and Table II. A start codon-embedded NdeI site, an additional stop codon, and an EcoRI site were engineered into PCR primers such that the PCR product could be subcloned into expression vector pMW172. Non-native splice sites in each construct are indicated by “~,” and sequencing verified that: construct R16~L1~R21 consisted of dystrophin residues Glu2012-Lys2146~Ala2515-Glu2686; construct R18~L2~R21, residues Gln2208-Gln2366~Arg2401-Glu2686; construct R15~L3~R23, residues Ile1874-Phe1966~Ala1972-Gly2096~Val2677-Glu2931; and construct R15~L4~R23, a hexaHis-tag followed by residues Ile1874-Phe1966~Ala1972-Ile1974~Asp2740-Glu2931.

Escherichia coli strain BL21 (Star)DE3 (Invitrogen) was transformed with the above plasmids. Bacteria were grown at 37°C in Luria-Bertani medium with 200 µg/mL of ampicillin, to an $A_{600\text{ nm}}$ of 0.8–1.0, and expression was induced by addition of 1 mM isopropyl-β-D-thiogalactoside. After 3–4 h, cells were harvested by centrifugation at 5000 × *g* for 10 min and frozen in liquid N₂. The frozen cell pellet (~10 mL, from 2 L of culture) was thawed for 10 min at 25°C and lysed by resuspension in 40 mL of Cellytic B (Sigma-Aldrich) containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/mL of leupeptin, and 10 mg/mL of aprotinin. After 15 min at 25°C, cell lysate was clarified by centrifugation at 45,000 × *g* for 15 min; centrifugation and all subsequent steps were performed at 4°C. For constructs R16~L1~R21, R18~L2~R21, and R15~L3~R23, the supernatant was loaded onto an anion exchange column (Whatman DE-52, 2.5 × 30 cm²) pre-equilibrated with 20 mM Hepes (pH 7.0), 1 mM dithiothreitol, 1 mM sodium azide, and eluted at 35 mL/h with a 325 × 325 mL² gradient of 0–0.5 M sodium chloride in Hepes buffer; fractions were collected at 12 min intervals. The expressed protein, identified by SDS-PAGE, eluted about halfway through the gradient. Solid ammonium sulfate was added to the pooled peak fractions to a final concentration of 1.6 M, and the material was applied to a 1.5 × 30 cm² column of Butyl ToyoPearl 650 M (Tosoh Bioscience) in 1.6 M ammonium sulfate, 20 mM Hepes (pH 7.0), 1 mM dithiothreitol, 1 mM sodium azide. The column was eluted at 10 mL/h with a descending gradient of 1.6–0 M ammonium sulfate in 150 mL. Fractions were collected at 10 min intervals, and fractions containing the purified protein were identified by SDS-PAGE, pooled, and

dialyzed against 100 volumes of PBS, with two changes. For construct R15~L4~R23 a final concentration of 6 M urea was added to crude lysate, and the cell pellet was resuspended in 6 M urea and centrifuged at 45,000 × *g* for 15 min 3 ×. Crude lysate and urea washes were combined and applied to a Ni-NTA Superflow column. Protein was eluted according to manufacturer's instructions. Concentration was determined from the A280 nm using an extinction coefficient of 1.313 at 1 mg/mL, calculated from the amino acid composition.

Stable monomer was ultimately purified by gel permeation chromatography in PBS and kept on ice for AFM studies. Immediately before use, any protein aggregates were removed by centrifugation 2°C for 1 h; and monodispersity was verified by dynamic light scattering.

CD Measurements

CD spectra were measured and analyzed as before [Bhasin et al., 2005] at a number of temperatures using a 1 mm path length cell on a Jasco J715 spectropolarimeter in the same buffer (PBS, pH 7.4) as that used in the AFM experiments. The instrument was calibrated with d-10-camphorsulfonic acid. Samples were equilibrated at each temperature for 20 min before taking measurements. Each spectrum was the average of three measurements. CD spectra for each nano-construct were also measured at 25°C with 40% v/v TFE.

Fluorescence Spectroscopy

All tryptophan fluorescence experiments were carried out as described elsewhere [Johnson et al., 2007b] using a UV fluorometer from Photon Technology Instruments with a set excitation wavelength of 275 nm. The emission spectrum was monitored between 310 and 370 nm for each scan. Samples consisted of 480 µL of PBS buffer (pH = 7.5) and 20 µL of 1 mg/mL protein utilizing a 1 mL cuvette with 1 cm path length. Temperature scans from 21 to 80°C were collected at 2°C increments with appropriate time to thermoequilibrate at each temperature. A blank buffer sample spectrum was also collected for background subtraction. Emission intensities at 350 nm were analyzed using the previously reported methods.

Atomic Force Spectroscopy

Protein solution (50 µL of 0.1 mg/mL) was adsorbed on freshly cleaved mica for 30 min at room temperature per [Bhasin et al., 2005]. All measurements were carried out in PBS using a Nanoscope-E Multimode AFM (Digital Instruments, Santa Barbara, CA) equipped with a liquid cell. Sharpened silicon nitride (Si₃N₄) cantilevers (Park Scientific, Sunnyvale, CA) of nominal spring constant $k_C = 10$ pN/nm were typically used, with equivalent results obtained using 30 pN/nm cantilevers. k_C was measured for each cantilever using the manufacturer's directions at each temperature, and additional calibrations were performed as described previously. Experiments were done at imposed displacement rates of 1 nm/msec = 1 µm/sec. Thousands of surface to tip contacts were collected and analyzed with the aid of a

semiautomated, visual analysis program custom written in C++. Since protein unfolding events are stochastic and the experiment intrinsically random in many ways, collecting and analyzing thousands of peaks is necessary to provide an accurate statistical survey of extensible unfolding. Initial results at the beginning of a many hour experiment were similar to those obtained at the end of the experiment. Force spectrograms, or sawtooth patterns for each construct were analyzed by categorizing each according to the number of peaks (N_{pk}) as well as peak-to-peak lengths (l_{pk-pk}).

Acknowledgments

The authors gratefully acknowledge support from the NIH (NIAMS, NHLBI, and NIBIB), the Muscular Dystrophy Association (MDA), and the NSF (including Penn's NSEC—NanoBio Interface Center). Experiments on the dystrophin rod domain at different temperatures and pulling rates were conducted by A. E. X. Brown as a visitor to the Laboratory of Prof. Matthias Rief (Technical University of Munich, Physics), and they also acknowledge the opportunity to use their instruments and all of the assistance.

References

Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC. 2006. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. *Mol Ther* 14:401–407.

Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC. 2007. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. *BMC Med Genet* 8:43–51.

Bérout C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Caemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M. 2007. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. *Hum Mutat* 28:196–202.

Bhasin N, Law R, Liao G, Safer D, Ellmer J, Discher BM, Sweeney HL, Discher DE. 2005. Molecular extensibility of mini-dystrophins and a dystrophin rod construct. *J Mol Biol* 352:795–806.

Engler A, Sheehan A, Sen S, Bonnemann C, Sweeney HL, Discher DE. 2004. Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications of stiff or soft microenvironments. *J Cell Biol* 166(6):877–887.

Engler A, Carag C, Johnson C, Raab M, Tang H-Y, Speicher D, Sanger J, Sanger J, Discher DE. 2008. Embryonic cardiomyocytes beat best on a ma-

trix with heart-like elasticity: scar-like rigidity inhibits beating. *J Cell Sci* 121:3794–3802.

Fokkema IF, den Dunnen JT, Taschner PE. 2005. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. *Hum Mutat* 26(2):63–68.

Freund AA, Scola RH, Arndt RC, Lorenzoni PJ, Kay CK, Werneck LC. 2007. Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach. *Arq Neuropsiquiatr* 65:73–76.

Ishijima A, Kojima H, Higuchi H, Harada Y, Funatsu T, Yanagida T. 1996. Multiple- and single-molecule analysis of the actomyosin motor by nanometer-piconewton manipulation with a microneedle: unitary steps and forces. *Biophys J* 70:383–400.

Johnson CP, Tang HY, Carag C, Speicher DW, Discher DE. 2007a. Forced unfolding of proteins within cells. *Science* 317:663–666.

Johnson C, Massimiliano G, Ortiz V, Bhasin N, Harper S, Speicher D, Gallagher P, Discher DE. 2007b. A pathogenic proline mutation in the linker between spectrin repeats: disease due to spectrin unfolding. *Blood* 109(8):3538–3543.

Kahana E, Flood G, Gratzner WB. 1997. Physical properties of dystrophin rod domain. *Cell Motil Cytoskeleton* 36:246–252.

Law R, Carl P, Harper S, Dalhaimer P, Speicher DW, Discher DE. 2003. Cooperativity in forced unfolding of tandem spectrin repeats. *Biophys J* 84:533–544.

Lewis C, Carberry S, Ohlendieck K. 2009. Proteomic profiling of x-linked muscular dystrophy. *J Muscle Res Cell Motil* 30:267–269.

Li H, Linke WA, Oberhauser AF, Carrion-Vazquez M, Kerkvliet JG, Lu H. 2002. Reverse engineering of the giant muscle protein titin. *Nature* 418:998–1002.

Marszalek PE, Oberhauser AF, Li H, Fernandez JM. 2003. The force-driven conformations of heparin studied with single molecule force microscopy. *Biophys J* 85:2696–2704.

Mirza A, Sagathevan M, Sahni N, Choi L, Menhart N. 2010. A biophysical map of the dystrophin rod. *Biochim Biophys Acta* 1804(9):1796–1809.

Ortiz V, Nielsen SO, Klein ML, Discher DE. 2005. Unfolding a linker between helical repeats. *J Mol Biol* 349:638–647.

Rief M, Pascual J, Saraste M, Gaub HE. 1999. Single molecule force spectroscopy of spectrin repeats: low unfolding forces in helix bundles. *J Mol Biol* 286:553–561.

Ruszcak C, Mirza A, Menhart N. 2009. Differential stabilities of alternative exon-skipped rod motifs of dystrophin. *Biochim Biophys Acta* 1794:921–928.

Sun Y, Walker GC. 2005. Viscoelastic response of poly(dimethylsiloxane) in the adhesive interaction with AFM tips. *Langmuir* 21:8694–8702.

van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooij AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ. 2007. Local dystrophin restoration with antisense oligonucleotide PRO051. *N Engl J Med* 357:2677–2686.